amiodarone has been researched along with Left Ventricular Hypertrophy in 21 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether prophylactic amiodarone infusion prevents ventricular fibrillation after aortic cross-clamp release and attenuates cytokine production in patients with left ventricular hypertrophy undergoing cardiac surgery." | 9.30 | Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial. ( Kagaya, S; Kuroda, M; Mita, N; Miyoshi, S, 2019) |
| "Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy." | 9.08 | Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. ( Colling, C; Deedwania, PC; Fisher, SG; Fletcher, RD; Lazzeri, D; Lewis, HD; Massie, BM; Singh, BN; Singh, SN, 1995) |
| "We present the case of intentional caffeine poisoning after ingestion of tablets containing guarana extract, complicated by atrial fibrillation." | 7.80 | Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose. ( Biedroń, W; Ciszowski, K; Gomólka, E, 2014) |
| "To investigate whether prophylactic amiodarone infusion prevents ventricular fibrillation after aortic cross-clamp release and attenuates cytokine production in patients with left ventricular hypertrophy undergoing cardiac surgery." | 5.30 | Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial. ( Kagaya, S; Kuroda, M; Mita, N; Miyoshi, S, 2019) |
| "Although amiodarone was effective in suppressing ventricular arrhythmias and improving ventricular function, it did not reduce the incidence of sudden death or prolong survival among patients with heart failure, except for a trend toward reduced mortality among those with nonischemic cardiomyopathy." | 5.08 | Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. ( Colling, C; Deedwania, PC; Fisher, SG; Fletcher, RD; Lazzeri, D; Lewis, HD; Massie, BM; Singh, BN; Singh, SN, 1995) |
| "Atrial fibrillation (AF) guidelines recommend amiodarone as the preferred antiarrhythmic medication (AAM) in patients with left ventricular hypertrophy (LVH), due to potential pro-arrhythmic risk with other AAM." | 4.31 | Mortality associated with antiarrhythmic medication for atrial fibrillation among patients with left ventricular hypertrophy. ( Adabag, S; Agdamag, AC; Angsubhakorn, N; Chen, LY; Gravely, A; Westanmo, A, 2023) |
| " Dronedarone is an antiarrhythmic agent that was recently approved for the treatment of atrial fibrillation." | 3.85 | Dronedarone produces early regression of myocardial remodelling in structural heart disease. ( Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML, 2017) |
| "Despite sparse clinical data, current atrial fibrillation (AF) guidelines favor amiodarone as a drug of choice for patients with left ventricular hypertrophy (LVH)." | 3.80 | Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. ( Chung, MK; Chung, R; Houghtaling, PL; Lindsay, BD; Niebauer, MJ; Tchou, M; Tchou, PJ, 2014) |
| "We present the case of intentional caffeine poisoning after ingestion of tablets containing guarana extract, complicated by atrial fibrillation." | 3.80 | Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose. ( Biedroń, W; Ciszowski, K; Gomólka, E, 2014) |
| "Acute myocardial infarction was induced in mice (AMI), while sham operated animals served as controls (SHAM)." | 1.39 | Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice. ( Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C, 2013) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "1." | 1.29 | Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. ( Borrel, E; Fagret, D; Vanzetto, G; Wolf, JE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Naccarelli, GV | 1 |
| Kowey, PR | 1 |
| Agdamag, AC | 1 |
| Westanmo, A | 1 |
| Gravely, A | 1 |
| Angsubhakorn, N | 1 |
| Chen, LY | 1 |
| Adabag, S | 1 |
| Quintana-Villamandos, B | 1 |
| Gomez de Diego, JJ | 1 |
| Delgado-Martos, MJ | 1 |
| Muñoz-Valverde, D | 1 |
| Soto-Montenegro, ML | 1 |
| Desco, M | 1 |
| Delgado-Baeza, E | 1 |
| Mita, N | 1 |
| Kagaya, S | 1 |
| Miyoshi, S | 1 |
| Kuroda, M | 1 |
| Dalia, AA | 1 |
| Essandoh, MK | 1 |
| Mourouzis, I | 1 |
| Kostakou, E | 1 |
| Galanopoulos, G | 1 |
| Mantzouratou, P | 1 |
| Pantos, C | 1 |
| Chung, R | 1 |
| Houghtaling, PL | 1 |
| Tchou, M | 1 |
| Niebauer, MJ | 1 |
| Lindsay, BD | 1 |
| Tchou, PJ | 1 |
| Chung, MK | 1 |
| Li, H | 1 |
| Zhou, Y | 1 |
| Jiang, B | 1 |
| Zhao, X | 1 |
| Li, X | 1 |
| Yang, X | 1 |
| Jiang, W | 1 |
| Ciszowski, K | 1 |
| Biedroń, W | 1 |
| Gomólka, E | 1 |
| Bobbo, M | 1 |
| Pinamonti, B | 1 |
| Merlo, M | 1 |
| Stolfo, D | 1 |
| Iorio, A | 1 |
| Ramani, F | 1 |
| Barbati, G | 1 |
| Carriere, C | 1 |
| Massa, L | 1 |
| Poli, S | 1 |
| Scapol, S | 1 |
| Gigli, M | 1 |
| Di Lenarda, A | 1 |
| Sinagra, G | 1 |
| Radulescu, B | 1 |
| Imperiale, A | 1 |
| Germain, P | 1 |
| Ohlmann, P | 1 |
| Horowitz, JD | 1 |
| Chirkov, YY | 1 |
| Kennedy, JA | 1 |
| Sverdlov, AL | 1 |
| Morita, Y | 1 |
| Mizuno, J | 1 |
| Yoshimura, T | 1 |
| Morita, S | 1 |
| Potpara, TS | 1 |
| Polovina, MM | 1 |
| Licina, MM | 1 |
| Mujovic, NM | 1 |
| Marinkovic, JM | 1 |
| Petrovic, M | 1 |
| Vujisic-Tesic, B | 1 |
| Lip, GY | 1 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Singh, SN | 1 |
| Fletcher, RD | 1 |
| Fisher, SG | 1 |
| Singh, BN | 1 |
| Lewis, HD | 1 |
| Deedwania, PC | 1 |
| Massie, BM | 1 |
| Colling, C | 1 |
| Lazzeri, D | 1 |
| Kopp, DE | 1 |
| Blakeman, BP | 1 |
| Kall, JG | 1 |
| Olshansky, B | 1 |
| Kinder, CA | 1 |
| Wilber, DJ | 1 |
| Fagret, D | 1 |
| Wolf, JE | 1 |
| Vanzetto, G | 1 |
| Borrel, E | 1 |
| Khalighi, K | 1 |
| Daly, B | 1 |
| Leino, EV | 1 |
| Shorofsky, SR | 1 |
| Kavesh, NG | 1 |
| Peters, RW | 1 |
| Gold, MR | 1 |
| Aggarwal, A | 1 |
| Boriani, G | 1 |
| Rapezzi, C | 1 |
| Biffi, M | 1 |
| Branzi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
1 review available for amiodarone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
2 trials available for amiodarone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Prophylactic Effect of Amiodarone Infusion on Reperfusion Ventricular Fibrillation After Release of Aortic Cross-Clamp in Patients with Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: ARandomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Double-Blind Met | 2019 |
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
Topics: Actuarial Analysis; Aged; Amiodarone; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Death, Sud | 1995 |
18 other studies available for amiodarone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Should we limit antiarrhythmic drug choice in patients with left ventricular hypertrophy?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypertrophy, Left Ventricular | 2023 |
Mortality associated with antiarrhythmic medication for atrial fibrillation among patients with left ventricular hypertrophy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypertrophy, Left Ventricular | 2023 |
Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrial Remodeling; Dronedarone; Heart Diseases; Humans; Hy | 2017 |
Preventing Ventricular Fibrillation in Patients With Left Ventricular Hypertrophy Undergoing Aortic Valve Replacement: Time to Consider Prophylactic Amiodarone Infusion.
Topics: Amiodarone; Aortic Valve; Aortic Valve Stenosis; Heart Valve Prosthesis; Humans; Hypertrophy, Left V | 2019 |
Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.
Topics: Amiodarone; Animals; Calcium-Binding Proteins; Dronedarone; Hypertrophy, Left Ventricular; Male; Mic | 2013 |
Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Female; Humans; Hyper | 2014 |
Dual effects of amiodarone on pacemaker currents in hypertrophied ventricular myocytes isolated from spontaneously hypertensive rats.
Topics: Amiodarone; Animals; Biological Clocks; Cell Separation; Cells, Cultured; Dose-Response Relationship | 2014 |
Acute caffeine poisoning resulting in atrial fibrillation after guarana extract overdose.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Caffeine; Drug Overdose; Echocardiog | 2014 |
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin- | 2017 |
Severe ventricular arrhythmias in a patient with cardiac sarcoidosis: insights from MRI and PET imaging and importance of early corticosteroid therapy.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Defibrillators, Implantable; Humans; Hy | 2010 |
Efficacy of amiodarone on refractory ventricular fibrillation resistant to lidocaine and cardioversion during weaning from cardiopulmonary bypass in aortic valve replacement for severe aortic stenosis with left ventricular hypertrophy.
Topics: Aged; Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Aortic Valve; Aortic Valve Stenosis; | 2010 |
The impact of dilated left atrium on rhythm control in patients with newly diagnosed persistent atrial fibrillation: the Belgrade atrial fibrillation project.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countersh | 2011 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
Predictors of defibrillation energy requirements with nonepicardial lead systems.
Topics: Amiodarone; Defibrillators, Implantable; Electric Countershock; Electrodes, Implanted; Equipment Des | 1995 |
Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Amiodarone; Aortic Valve Stenosis; Contrast Media; Digoxin; Fema | 1993 |
Clinical predictors of transvenous defibrillation energy requirements.
Topics: Amiodarone; Anti-Arrhythmia Agents; Body Constitution; Cohort Studies; Defibrillators, Implantable; | 1997 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Combined Modality Therapy; Defibrillators, Implanta | 2002 |